{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:12:29Z","timestamp":1793643149871,"version":"4.5.1"},"reference-count":126,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T00:00:00Z","timestamp":1638835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T00:00:00Z","timestamp":1638835200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Immunol"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1038\/s41577-021-00662-4","type":"journal-article","created":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T08:03:37Z","timestamp":1638864217000},"page":"57-65","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":301,"title":["SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact"],"prefix":"10.1038","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1504-9213","authenticated-orcid":false,"given":"Marc","family":"Lipsitch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4121-776X","authenticated-orcid":false,"given":"Florian","family":"Krammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gili","family":"Regev-Yochay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaniv","family":"Lustig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran D.","family":"Balicer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,7]]},"reference":[{"key":"662_CR1","doi-asserted-by":"crossref","first-page":"434","DOI":"10.4269\/ajtmh.13-0264","volume":"89","author":"E Gotuzzo","year":"2013","unstructured":"Gotuzzo, E., Yactayo, S. & C\u00f3rdova, E. Efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years. Am. J. Trop. Med. Hyg. 89, 434\u2013444 (2013).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"662_CR2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009509","volume":"17","author":"JW Yewdell","year":"2021","unstructured":"Yewdell, J. W. Individuals cannot rely on COVID-19 herd immunity: durable immunity to viral disease is limited to viruses with obligate viremic spread. PLoS Pathog. 17, e1009509 (2021).","journal-title":"PLoS Pathog."},{"key":"662_CR3","first-page":"1055","volume":"63","author":"WA Orenstein","year":"1985","unstructured":"Orenstein, W. A. et al. Field evaluation of vaccine efficacy. Bull. World Health Organ. 63, 1055\u20131068 (1985).","journal-title":"Bull. World Health Organ."},{"key":"662_CR4","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/EDE.0000000000000003","volume":"25","author":"JJ O\u2019Hagan","year":"2014","unstructured":"O\u2019Hagan, J. J., Lipsitch, M. & Hern\u00e1n, M. A. Estimating the per-exposure effect of infectious disease interventions. Epidemiology 25, 134\u2013138 (2014).","journal-title":"Epidemiology"},{"key":"662_CR5","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/s41591-020-0887-3","volume":"26","author":"M Lipsitch","year":"2020","unstructured":"Lipsitch, M., Kahn, R. & Mina, M. J. Antibody testing will enhance the power and accuracy of COVID-19-prevention trials. Nat. Med. 26, 818\u2013819 (2020).","journal-title":"Nat. Med."},{"key":"662_CR6","doi-asserted-by":"publisher","DOI":"10.1101\/2021.07.15.21260595","author":"R Kahn","year":"2021","unstructured":"Kahn, R., Schrag, S. J., Verani, J. R. & Lipsitch, M. Identifying and alleviating bias due to differential depletion of susceptible people in post-marketing evaluations of COVID-19 vaccines. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2021.07.15.21260595 (2021).","journal-title":"medRxiv"},{"key":"662_CR7","doi-asserted-by":"crossref","first-page":"221","DOI":"10.7326\/M20-6169","volume":"174","author":"DV Mehrotra","year":"2021","unstructured":"Mehrotra, D. V. et al. Clinical endpoints for evaluating efficacy in COVID-19 vaccine trials. Ann. Intern. Med. 174, 221\u2013228 (2021).","journal-title":"Ann. Intern. Med."},{"key":"662_CR8","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","volume":"397","author":"M Voysey","year":"2020","unstructured":"Voysey, M. et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 397, 99\u2013111 (2020).","journal-title":"Lancet"},{"key":"662_CR9","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603\u20132615 (2020).","journal-title":"N. Engl. J. Med."},{"key":"662_CR10","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403\u2013416 (2021).","journal-title":"N. Engl. J. Med."},{"key":"662_CR11","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","volume":"384","author":"J Sadoff","year":"2021","unstructured":"Sadoff, J. et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N. Engl. J. Med. 384, 2187\u20132201 (2021).","journal-title":"N. Engl. J. Med."},{"key":"662_CR12","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0140-6736(21)00432-3","volume":"397","author":"M Voysey","year":"2021","unstructured":"Voysey, M. et al. Single dose administration, and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet 397, 881\u2013891 (2021).","journal-title":"Lancet"},{"key":"662_CR13","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1126\/science.abe5938","volume":"370","author":"M Lipsitch","year":"2020","unstructured":"Lipsitch, M. & Dean, N. E. Understanding COVID-19 vaccine efficacy. Science 370, 763\u2013765 (2020).","journal-title":"Science"},{"key":"662_CR14","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1001\/jama.2020.25053","volume":"325","author":"A Rid","year":"2021","unstructured":"Rid, A., Lipsitch, M. & Miller, F. G. The ethics of continuing placebo in SARS-CoV-2 vaccine trials. JAMA 325, 219\u2013220 (2021).","journal-title":"JAMA"},{"key":"662_CR15","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1056\/NEJMoa2110345","volume":"385","author":"SJ Thomas","year":"2021","unstructured":"Thomas, S. J. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. N. Engl. J. Med. 385, 1761\u20131773 (2021).","journal-title":"N. Engl. J. Med."},{"key":"662_CR16","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1056\/NEJMoa2113017","volume":"385","author":"HM El Sahly","year":"2021","unstructured":"El Sahly, H. M. et al. Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase. N. Engl. J. Med. 385, 1774\u20131785 (2021).","journal-title":"N. Engl. J. Med."},{"key":"662_CR17","unstructured":"Pfizer. BNT162b2 [COMIRNATY (COVID-19 Vaccine, mRNA)] Evaluation of a Booster Dose (Third Dose). Vaccines and Related Biological Products Advisory Committee Briefing Document FDA.gov https:\/\/www.fda.gov\/media\/152161\/download (2021)."},{"key":"662_CR18","unstructured":"Moderna. Moderna Highlights New Clinical Data on its COVID-19 Vaccine. Moderna Inc https:\/\/investors.modernatx.com\/news-releases\/news-release-details\/moderna-highlights-new-clinical-data-its-covid-19-vaccine (2021)."},{"key":"662_CR19","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1056\/NEJMoa2103055","volume":"384","author":"V Shinde","year":"2021","unstructured":"Shinde, V. et al. Efficacy of NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant. N. Engl. J. Med. 384, 1899\u20131909 (2021).","journal-title":"N. Engl. J. Med."},{"key":"662_CR20","doi-asserted-by":"publisher","DOI":"10.1101\/2021.02.10.21251247","author":"SA Madhi","year":"2021","unstructured":"Madhi, S. A. et al. Safety and efficacy of the ChAdOx1 nCoV-19 (AZD1222) Covid-19 vaccine against the B.1.351 variant in South Africa. N. Engl. J. Med. https:\/\/doi.org\/10.1101\/2021.02.10.21251247 (2021).","journal-title":"N. Engl. J. Med."},{"key":"662_CR21","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab182","author":"N Eyal","year":"2021","unstructured":"Eyal, N. & Lipsitch, M. How to test SARS-CoV-2 vaccines ethically even after one is available. Clin. Infect. Dis. https:\/\/doi.org\/10.1093\/cid\/ciab182 (2021).","journal-title":"Clin. Infect. Dis."},{"key":"662_CR22","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMoa2108891","volume":"385","author":"JL Bernal","year":"2021","unstructured":"Bernal, J. L. et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. N. Engl. J. Med. 385, 585\u2013594 (2021).","journal-title":"N. Engl. J. Med."},{"key":"662_CR23","doi-asserted-by":"publisher","DOI":"10.1101\/2021.08.24.21262423","author":"Y Goldberg","year":"2021","unstructured":"Goldberg, Y. et al. Waning immunity of the BNT162b2 vaccine: a nationwide study from Israel. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2021.08.24.21262423 (2021).","journal-title":"medRxiv"},{"key":"662_CR24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2114114","author":"H Chemaitelly","year":"2021","unstructured":"Chemaitelly, H. et al. Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa2114114 (2021).","journal-title":"N. Engl. J. Med."},{"key":"662_CR25","first-page":"1284","volume":"70","author":"HM Scobie","year":"2021","unstructured":"Scobie, H. M. et al. Monitoring incidence of COVID-19 cases, hospitalizations, and deaths, by vaccination status - 13 U.S. Jurisdictions, April 4-July 17, 2021. MMWR 70, 1284\u20131290 (2021).","journal-title":"MMWR"},{"key":"662_CR26","doi-asserted-by":"publisher","DOI":"10.1101\/2021.08.06.21261707","author":"A Puranik","year":"2021","unstructured":"Puranik, A. et al. Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2021.08.06.21261707 (2021).","journal-title":"medRxiv"},{"key":"662_CR27","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S0140-6736(21)02183-8","volume":"398","author":"SY Tartof","year":"2021","unstructured":"Tartof, S. Y. et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet 398, 1407\u20131416 (2021).","journal-title":"Lancet"},{"key":"662_CR28","doi-asserted-by":"publisher","DOI":"10.1101\/2021.08.21.21261501","author":"T Cerqueira-Silva","year":"2021","unstructured":"Cerqueira-Silva, T. et al. Influence of age on the effectiveness and duration of protection in vaxzevria and coronavac vaccines. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2021.08.21.21261501 (2021).","journal-title":"medRxiv"},{"key":"662_CR29","first-page":"1337","volume":"70","author":"WH Self","year":"2021","unstructured":"Self, W. H. et al. Comparative effectiveness of moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) vaccines in preventing COVID-19 hospitalizations among adults without immunocompromising conditions - United States, March-August 2021. MMWR 70, 1337\u20131343 (2021).","journal-title":"MMWR"},{"key":"662_CR30","doi-asserted-by":"publisher","DOI":"10.1101\/2021.09.23.21263864","author":"A Sharma","year":"2021","unstructured":"Sharma, A., Oda, G. & Holodniy, M. COVID-19 vaccine breakthrough infections in veterans health administration. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2021.09.23.21263864 (2021).","journal-title":"medRxiv"},{"key":"662_CR31","doi-asserted-by":"publisher","DOI":"10.1126\/science.abm0620","author":"BA Cohn","year":"2021","unstructured":"Cohn, B. A., Cirillo, P. M., Murphy, C. C., Krigbaum, N. Y. & Wallace, A. W. SARS-CoV-2 vaccine protection and deaths among US veterans during 2021. Science https:\/\/doi.org\/10.1126\/science.abm0620 (2021).","journal-title":"Science"},{"key":"662_CR32","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(21)00947-8","volume":"397","author":"EJ Haas","year":"2021","unstructured":"Haas, E. J. et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet 397, 1819\u20131829 (2021).","journal-title":"Lancet"},{"key":"662_CR33","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1056\/NEJMoa2101765","volume":"384","author":"N Dagan","year":"2021","unstructured":"Dagan, N. et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N. Engl. J. Med. 384, 1412\u20131423 (2021).","journal-title":"N. Engl. J. Med."},{"key":"662_CR34","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1056\/NEJMc2104281","volume":"384","author":"S Roest","year":"2021","unstructured":"Roest, S., Hoek, R. A. S. & Manintveld, O. C. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N. Engl. J. Med. 384, 1968\u20131970 (2021).","journal-title":"N. Engl. J. Med."},{"key":"662_CR35","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1038\/s41591-021-01490-8","volume":"27","author":"N Dagan","year":"2021","unstructured":"Dagan, N. et al. Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy. Nat. Med. 27, 1693\u20131695 (2021).","journal-title":"Nat. Med."},{"key":"662_CR36","first-page":"495","volume":"70","author":"MG Thompson","year":"2021","unstructured":"Thompson, M. G. et al. Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers - Eight U.S. Locations, December 2020-March 2021. MMWR 70, 495\u2013500 (2021).","journal-title":"MMWR"},{"key":"662_CR37","first-page":"2060","volume":"45","author":"M Lipsitch","year":"2016","unstructured":"Lipsitch, M., Jha, A. & Simonsen, L. Observational studies and the difficult quest for causality: lessons from vaccine effectiveness and impact studies. Int. J. Epidemiol. 45, 2060\u20132074 (2016).","journal-title":"Int. J. Epidemiol."},{"key":"662_CR38","doi-asserted-by":"crossref","first-page":"4013","DOI":"10.1016\/j.vaccine.2021.05.099","volume":"39","author":"MK Patel","year":"2021","unstructured":"Patel, M. K. et al. Evaluation of post-introduction COVID-19 vaccine effectiveness: summary of interim guidance of the World Health Organization. Vaccine 39, 4013\u20134024 (2021).","journal-title":"Vaccine"},{"key":"662_CR39","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/aje\/kww064","volume":"184","author":"SG Sullivan","year":"2016","unstructured":"Sullivan, S. G., Tchetgen Tchetgen, E. J. & Cowling, B. J. Theoretical basis of the test-negative study design for assessment of influenza vaccine effectiveness. Am. J. Epidemiol. 184, 345\u2013353 (2016).","journal-title":"Am. J. Epidemiol."},{"key":"662_CR40","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/EDE.0000000000001116","volume":"31","author":"H Chua","year":"2020","unstructured":"Chua, H. et al. The use of test-negative controls to monitor vaccine effectiveness: a systematic review of methodology. Epidemiology 31, 43\u201364 (2020).","journal-title":"Epidemiology"},{"key":"662_CR41","doi-asserted-by":"publisher","DOI":"10.1101\/2021.03.16.21253686","author":"I Yelin","year":"2021","unstructured":"Yelin, I. et al. Associations of the BNT162b2 COVID-19 vaccine effectiveness with patient age and comorbidities at daily resolution. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2021.03.16.21253686 (2021).","journal-title":"medRxiv"},{"key":"662_CR42","doi-asserted-by":"crossref","first-page":"100150","DOI":"10.1016\/j.lanepe.2021.100150","volume":"7","author":"G Regev-Yochay","year":"2021","unstructured":"Regev-Yochay, G. et al. Decreased infectivity following BNT162b2 vaccination: a prospective cohort study in Israel. Lancet Reg. Health Eur. 7, 100150 (2021).","journal-title":"Lancet Reg. Health Eur."},{"key":"662_CR43","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.3904701","author":"SR Singer","year":"2021","unstructured":"Singer, S. R. et al. Effectiveness of BNT162b2 mRNA COVID-19 vaccine against SARS-CoV-2 variant beta (B.1.351) among persons identified through contact tracing in Israel. Preprint at SSRN https:\/\/doi.org\/10.2139\/ssrn.3904701 (2021).","journal-title":"SSRN"},{"key":"662_CR44","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1016\/j.vaccine.2021.06.011","volume":"39","author":"M Lipsitch","year":"2021","unstructured":"Lipsitch, M. & Kahn, R. Interpreting vaccine efficacy trial results for infection and transmission. Vaccine 39, 4082\u20134088 (2021).","journal-title":"Vaccine"},{"key":"662_CR45","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1056\/NEJMoa2109072","volume":"385","author":"M Bergwerk","year":"2021","unstructured":"Bergwerk, M. et al. Covid-19 breakthrough infections in vaccinated health care workers. N. Engl. J. Med. 385, 1474\u20131484 (2021).","journal-title":"N. Engl. J. Med."},{"key":"662_CR46","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/S0140-6736(21)00790-X","volume":"397","author":"VJ Hall","year":"2021","unstructured":"Hall, V. J. et al. COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. Lancet 397, 1725\u20131735 (2021).","journal-title":"Lancet"},{"key":"662_CR47","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2114583","author":"EG Levin","year":"2021","unstructured":"Levin, E. G. et al. Waning immune humoral response to BNT162b2 covid-19 vaccine over 6 months. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/nejmoa2114583 (2021).","journal-title":"N. Engl. J. Med."},{"key":"662_CR48","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","volume":"27","author":"DS Khoury","year":"2021","unstructured":"Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. 27, 1205\u20131211 (2021).","journal-title":"Nat. Med."},{"key":"662_CR49","doi-asserted-by":"crossref","first-page":"4423","DOI":"10.1016\/j.vaccine.2021.05.063","volume":"39","author":"KA Earle","year":"2021","unstructured":"Earle, K. A. et al. Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine 39, 4423\u20134428 (2021).","journal-title":"Vaccine"},{"key":"662_CR50","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-832531\/v1","author":"D Goldblatt","year":"2021","unstructured":"Goldblatt, D. et al. A population-based threshold of protection for COVID-19 vaccines. Preprint at Res. Sq. https:\/\/doi.org\/10.21203\/rs.3.rs-832531\/v1 (2021).","journal-title":"Res. Sq."},{"key":"662_CR51","doi-asserted-by":"publisher","DOI":"10.1101\/2021.08.09.21261290","author":"PB Gilbert","year":"2021","unstructured":"Gilbert, P. B. et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy trial. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2021.08.09.21261290 (2021).","journal-title":"medRxiv"},{"key":"662_CR52","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1128\/CVI.00131-10","volume":"17","author":"SA Plotkin","year":"2010","unstructured":"Plotkin, S. A. Correlates of protection induced by vaccination. Clin. Vaccine Immunol. 17, 1055\u20131065 (2010).","journal-title":"Clin. Vaccine Immunol."},{"key":"662_CR53","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1093\/cid\/cis238","volume":"54","author":"SA Plotkin","year":"2012","unstructured":"Plotkin, S. A. & Gilbert, P. B. Nomenclature for immune correlates of protection after vaccination. Clin. Infect. Dis. 54, 1615\u20131617 (2012).","journal-title":"Clin. Infect. Dis."},{"key":"662_CR54","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1056\/NEJMc2032195","volume":"384","author":"AT Widge","year":"2021","unstructured":"Widge, A. T. et al. Durability of responses after SARS-CoV-2 mRNA-1273 vaccination. N. Engl. J. Med. 384, 80\u201382 (2021).","journal-title":"N. Engl. J. Med."},{"key":"662_CR55","doi-asserted-by":"crossref","first-page":"100208","DOI":"10.1016\/j.lanepe.2021.100208","volume":"10","author":"P Naaber","year":"2021","unstructured":"Naaber, P. et al. Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study. Lancet Reg. Health Eur. 10, 100208 (2021).","journal-title":"Lancet Reg. Health Eur."},{"key":"662_CR56","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1038\/s41591-021-01527-y","volume":"27","author":"A Choi","year":"2021","unstructured":"Choi, A. et al. Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis. Nat. Med. 27, 2025\u20132031 (2021).","journal-title":"Nat. Med."},{"key":"662_CR57","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1056\/NEJMoa066092","volume":"357","author":"IJ Amanna","year":"2007","unstructured":"Amanna, I. J., Carlson, N. E. & Slifka, M. K. Duration of humoral immunity to common viral and vaccine antigens. N. Engl. J. Med. 357, 1903\u20131915 (2007).","journal-title":"N. Engl. J. Med."},{"key":"662_CR58","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1038\/ni.3533","volume":"17","author":"AH Ellebedy","year":"2016","unstructured":"Ellebedy, A. H. et al. Defining antigen-specific plasmablast and memory B cell subsets in human blood after viral infection or vaccination. Nat. Immunol. 17, 1226\u20131234 (2016).","journal-title":"Nat. Immunol."},{"key":"662_CR59","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/nature06890","volume":"453","author":"J Wrammert","year":"2008","unstructured":"Wrammert, J. et al. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 453, 667\u2013671 (2008).","journal-title":"Nature"},{"key":"662_CR60","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41586-021-03647-4","volume":"595","author":"JS Turner","year":"2021","unstructured":"Turner, J. S. et al. SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans. Nature 595, 421\u2013425 (2021).","journal-title":"Nature"},{"key":"662_CR61","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S1074-7613(00)80541-5","volume":"8","author":"MK Slifka","year":"1998","unstructured":"Slifka, M. K., Antia, R., Whitmire, J. K. & Ahmed, R. Humoral immunity due to long-lived plasma cells. Immunity 8, 363\u2013372 (1998).","journal-title":"Immunity"},{"key":"662_CR62","doi-asserted-by":"publisher","DOI":"10.1101\/2021.08.01.21261297","author":"S Sheikh-Mohamed","year":"2021","unstructured":"Sheikh-Mohamed, S. et al. A mucosal antibody response is induced by intra-muscular SARS-CoV-2 mRNA vaccination. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2021.08.01.21261297 (2021).","journal-title":"medRxiv"},{"key":"662_CR63","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1093\/cid\/ciy770","volume":"68","author":"GT Ray","year":"2019","unstructured":"Ray, G. T. et al. Intraseason waning of influenza vaccine effectiveness. Clin. Infect. Dis. 68, 1623\u20131630 (2019).","journal-title":"Clin. Infect. Dis."},{"key":"662_CR64","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aao5945","volume":"10","author":"JA Lewnard","year":"2018","unstructured":"Lewnard, J. A. & Grad, Y. H. Vaccine waning and mumps re-emergence in the United States. Sci. Transl Med. 10, eaao5945 (2018).","journal-title":"Sci. Transl Med."},{"key":"662_CR65","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/S2213-2600(21)00220-4","volume":"9","author":"Y Lustig","year":"2021","unstructured":"Lustig, Y. et al. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers. Lancet Respir. Med. 9, 999\u20131009 (2021).","journal-title":"Lancet Respir. Med."},{"key":"662_CR66","first-page":"2100557","volume":"26","author":"Y Lustig","year":"2021","unstructured":"Lustig, Y. et al. Neutralising capacity against Delta (B.1.617.2) and other variants of concern following Comirnaty (BNT162b2, BioNTech\/Pfizer) vaccination in health care workers, Israel. Euro Surveill. 26, 2100557 (2021).","journal-title":"Euro Surveill."},{"key":"662_CR67","doi-asserted-by":"publisher","DOI":"10.1101\/2021.05.15.21257017","author":"HM Parry","year":"2021","unstructured":"Parry, H. M. et al. Extended interval BNT162b2 vaccination enhances peak antibody generation in older people. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2021.05.15.21257017 (2021).","journal-title":"medRxiv"},{"key":"662_CR68","doi-asserted-by":"publisher","DOI":"10.1101\/2021.09.17.21263532","author":"A Tauzin","year":"2021","unstructured":"Tauzin, A. et al. Strong humoral immune responses against SARS-CoV-2 spike after BNT162b2 mRNA vaccination with a sixteen-week interval between doses. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2021.09.17.21263532 (2021).","journal-title":"medRxiv"},{"key":"662_CR69","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.3927745","author":"DC Vinh","year":"2021","unstructured":"Vinh, D. C. et al. Real-world serologic responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail elderly - interim report from a prospective observational cohort study. Preprint at medRxiv https:\/\/doi.org\/10.2139\/ssrn.3927745 (2021).","journal-title":"medRxiv"},{"key":"662_CR70","doi-asserted-by":"crossref","first-page":"5699","DOI":"10.1016\/j.cell.2021.10.011","volume":"184","author":"RP Payne","year":"2021","unstructured":"Payne, R. P. et al. Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine. Cell 184, 5699\u20135714 (2021).","journal-title":"Cell"},{"key":"662_CR71","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.3910058","author":"P Kearns","year":"2021","unstructured":"Kearns, P. et al. Examining the immunological effects of COVID-19 vaccination in patients with conditions potentially leading to diminished immune response capacity \u2013 The OCTAVE Trial. SSRN https:\/\/doi.org\/10.2139\/ssrn.3910058 (2021).","journal-title":"SSRN"},{"key":"662_CR72","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.ccell.2021.06.014","volume":"39","author":"O Van Oekelen","year":"2021","unstructured":"Van Oekelen, O. et al. Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma. Cancer Cell 39, 1028\u20131030 (2021).","journal-title":"Cancer Cell"},{"key":"662_CR73","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1016\/j.ccell.2021.09.015","volume":"39","author":"A Aleman","year":"2021","unstructured":"Aleman, A. et al. Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma. Cancer Cell 39, 1442\u20131444 (2021).","journal-title":"Cancer Cell"},{"key":"662_CR74","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021013768","author":"M Mittelman","year":"2021","unstructured":"Mittelman, M. et al. Effectiveness of the BNT162b2mRNA Covid-19 vaccine in patients with hematological neoplasms in a nationwide mass vaccination setting. Blood https:\/\/doi.org\/10.1182\/blood.2021013768 (2021).","journal-title":"Blood"},{"key":"662_CR75","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/s41591-021-01318-5","volume":"27","author":"D Planas","year":"2021","unstructured":"Planas, D. et al. Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies. Nat. Med. 27, 917\u2013924 (2021).","journal-title":"Nat. Med."},{"key":"662_CR76","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.chom.2021.03.009","volume":"29","author":"VV Edara","year":"2021","unstructured":"Edara, V. V. et al. Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant. Cell Host Microbe 29, 516\u2013521.e3 (2021).","journal-title":"Cell Host Microbe"},{"key":"662_CR77","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1056\/NEJMc2103740","volume":"384","author":"X Shen","year":"2021","unstructured":"Shen, X. et al. Neutralization of SARS-CoV-2 variants B.1.429 and B.1.351. N. Engl. J. Med. 384, 2352\u20132354 (2021).","journal-title":"N. Engl. J. Med."},{"key":"662_CR78","doi-asserted-by":"publisher","DOI":"10.1101\/2021.07.21.21260961","author":"JM Carre\u00f1o","year":"2021","unstructured":"Carre\u00f1o, J. M. et al. Reduced neutralizing activity of post-SARS-CoV-2 vaccination serum against variants B.1.617.2, B.1.351, B.1.1.7+E484K and a sub-variant of C.37. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2021.07.21.21260961 (2021).","journal-title":"medRxiv"},{"key":"662_CR79","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1056\/NEJMc2102179","volume":"384","author":"K Wu","year":"2021","unstructured":"Wu, K. et al. Serum neutralizing activity elicited by mRNA-1273 vaccine. N. Engl. J. Med. 384, 1468\u20131470 (2021).","journal-title":"N. Engl. J. Med."},{"key":"662_CR80","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1056\/NEJMc2104974","volume":"385","author":"LJ Abu-Raddad","year":"2021","unstructured":"Abu-Raddad, L. J., Chemaitelly, H. & Butt, A. A. Effectiveness of the BNT162b2 Covid-19 vaccine against the B.1.1.7 and B.1.351 variants. N. Engl. J. Med. 385, 187\u2013189 (2021).","journal-title":"N. Engl. J. Med."},{"key":"662_CR81","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1038\/s41591-021-01413-7","volume":"27","author":"T Kustin","year":"2021","unstructured":"Kustin, T. et al. Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals. Nat. Med. 27, 1379\u20131384 (2021).","journal-title":"Nat. Med."},{"key":"662_CR82","volume":"10","author":"MGM Gomes","year":"2014","unstructured":"Gomes, M. G. M. et al. A missing dimension in measures of vaccination impacts. PLoS Pathog. 10, e1003849 (2014).","journal-title":"PLoS Pathog."},{"key":"662_CR83","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-39698-x","volume":"9","author":"KE Langwig","year":"2019","unstructured":"Langwig, K. E. et al. Limited available evidence supports theoretical predictions of reduced vaccine efficacy at higher exposure dose. Sci. Rep. 9, 3203 (2019).","journal-title":"Sci. Rep."},{"key":"662_CR84","doi-asserted-by":"publisher","DOI":"10.1101\/2021.08.15.21262077","author":"CH Luo","year":"2021","unstructured":"Luo, C. H. et al. Infection with the SARS-CoV-2 Delta variant is associated with higher infectious virus loads compared to the Alpha variant in both unvaccinated and vaccinated individuals. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2021.08.15.21262077 (2021).","journal-title":"medRxiv"},{"key":"662_CR85","doi-asserted-by":"crossref","first-page":"101129","DOI":"10.1016\/j.eclinm.2021.101129","volume":"40","author":"Y Wang","year":"2021","unstructured":"Wang, Y. et al. Transmission, viral kinetics and clinical characteristics of the emergent SARS-CoV-2 Delta VOC in Guangzhou, China. EClinicalMedicine 40, 101129 (2021).","journal-title":"EClinicalMedicine"},{"key":"662_CR86","doi-asserted-by":"publisher","DOI":"10.1101\/2021.05.08.443253","author":"P Mlcochova","year":"2021","unstructured":"Mlcochova, P. et al. SARS-CoV-2 B.1.617.2 Delta variant replication, sensitivity to neutralising antibodies and vaccine breakthrough. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2021.05.08.443253 (2021).","journal-title":"bioRxiv"},{"key":"662_CR87","doi-asserted-by":"publisher","DOI":"10.1101\/2021.08.05.455290","author":"A Escalera","year":"2021","unstructured":"Escalera, A., Gonzalez-Reiche, A. S., Aslam, S. & Mena, I. SARS-CoV-2 variants of concern have acquired mutations associated with an increased spike cleavage. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2021.08.05.455290 (2021).","journal-title":"bioRxiv"},{"key":"662_CR88","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01583-4","author":"P Tang","year":"2021","unstructured":"Tang, P. et al. BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the Delta (B.1.617.2) variant in Qatar. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-021-01583-4 (2021).","journal-title":"Nat. Med."},{"key":"662_CR89","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S1473-3099(14)70822-9","volume":"14","author":"NJ Andrews","year":"2014","unstructured":"Andrews, N. J. et al. Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study. Lancet Infect. Dis. 14, 839\u2013846 (2014).","journal-title":"Lancet Infect. Dis."},{"key":"662_CR90","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1093\/cid\/cix895","volume":"66","author":"M Voysey","year":"2018","unstructured":"Voysey, M. et al. Serotype-specific correlates of protection for pneumococcal carriage: an analysis of immunity in 19 countries. Clin. Infect. Dis. 66, 913\u2013920 (2018).","journal-title":"Clin. Infect. Dis."},{"key":"662_CR91","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMc2113468","volume":"385","author":"AR Falsey","year":"2021","unstructured":"Falsey, A. R. et al. SARS-CoV-2 neutralization with BNT162b2 vaccine dose 3. N. Engl. J. Med. 385, 1627\u20131629 (2021).","journal-title":"N. Engl. J. Med."},{"key":"662_CR92","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1056\/NEJMoa2114255","volume":"385","author":"YM Bar-On","year":"2021","unstructured":"Bar-On, Y. M. et al. Protection of BNT162b2 vaccine booster against Covid-19 in Israel. N. Engl. J. Med. 385, 1393\u20131400 (2021).","journal-title":"N. Engl. J. Med."},{"key":"662_CR93","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1056\/NEJMc2114290","volume":"385","author":"BY Reis","year":"2021","unstructured":"Reis, B. Y. et al. Effectiveness of BNT162b2 vaccine against delta variant in adolescents. N. Engl. J. Med. 385, 2101\u20132103 (2021).","journal-title":"N. Engl. J. Med."},{"key":"662_CR94","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)02249-2","author":"N Barda","year":"2021","unstructured":"Barda, N. et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. Lancet https:\/\/doi.org\/10.1016\/s0140-6736(21)02249-2 (2021).","journal-title":"Lancet"},{"key":"662_CR95","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41572-018-0002-y","volume":"4","author":"F Krammer","year":"2018","unstructured":"Krammer, F. et al. Influenza. Nat. Rev. Dis. Prim. 4, 3 (2018).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"662_CR96","doi-asserted-by":"publisher","DOI":"10.1101\/2021.07.12.21260377","author":"M Layan","year":"2021","unstructured":"Layan, M. et al. Impact of BNT162b2 vaccination and isolation on SARS-CoV-2 transmission in Israeli households: an observational study. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2021.07.12.21260377 (2021).","journal-title":"bioRxiv"},{"key":"662_CR97","doi-asserted-by":"publisher","DOI":"10.1101\/2021.02.16.21251535","author":"SM Kissler","year":"2021","unstructured":"Kissler, S. M. et al. Viral dynamics of SARS-CoV-2 variants in vaccinated and unvaccinated individuals. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2021.02.16.21251535 (2021).","journal-title":"medRxiv"},{"key":"662_CR98","doi-asserted-by":"publisher","DOI":"10.1101\/2021.08.18.21262237","author":"KB Pouwels","year":"2021","unstructured":"Pouwels, K. B. et al. Impact of Delta on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2021.08.18.21262237 (2021).","journal-title":"medRxiv"},{"key":"662_CR99","doi-asserted-by":"publisher","DOI":"10.1101\/2021.08.29.21262798","author":"M Levine-Tiefenbrun","year":"2021","unstructured":"Levine-Tiefenbrun, M. et al. Viral loads of Delta-variant SARS-CoV2 breakthrough infections following vaccination and booster with the BNT162b2 vaccine. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2021.08.29.21262798 (2021).","journal-title":"medRxiv"},{"key":"662_CR100","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1097\/EDE.0000000000001415","volume":"32","author":"L Kennedy-Shaffer","year":"2021","unstructured":"Kennedy-Shaffer, L., Kahn, R. & Lipsitch, M. Estimating vaccine efficacy against transmission via effect on viral load. Epidemiology 32, 820\u2013828 (2021).","journal-title":"Epidemiology"},{"key":"662_CR101","doi-asserted-by":"publisher","DOI":"10.1101\/2021.02.04.21251133","author":"D Follmann","year":"2021","unstructured":"Follmann, D. & Fay, M. Vaccine efficacy at a point in time. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2021.02.04.21251133 (2021).","journal-title":"medRxiv"},{"key":"662_CR102","doi-asserted-by":"publisher","DOI":"10.1101\/2021.08.20.21262158","author":"MC Shamier","year":"2021","unstructured":"Shamier, M. C. et al. Virological characteristics of SARS-CoV-2 vaccine breakthrough infections in health care workers. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2021.08.20.21262158 (2021).","journal-title":"medRxiv"},{"key":"662_CR103","doi-asserted-by":"publisher","DOI":"10.1101\/2021.07.27.21261224","author":"JA Hay","year":"2021","unstructured":"Hay, J. A., Kennedy-Shaffer, L. & Mina, M. J. Viral loads observed under competing strain dynamics. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2021.07.27.21261224 (2021).","journal-title":"medRxiv"},{"key":"662_CR104","doi-asserted-by":"publisher","DOI":"10.1101\/2021.09.28.21264260","author":"DW Eyre","year":"2021","unstructured":"Eyre, D. W. et al. The impact of SARS-CoV-2 vaccination on Alpha and Delta variant transmission. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2021.09.28.21264260 (2021).","journal-title":"medRxiv"},{"key":"662_CR105","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1056\/NEJMoa2110475","volume":"385","author":"N Barda","year":"2021","unstructured":"Barda, N. et al. Safety of the BNT162b2 mRNA Covid-19 Vaccine in a nationwide setting. N. Engl. J. Med. 385, 1078\u20131090 (2021).","journal-title":"N. Engl. J. Med."},{"key":"662_CR106","doi-asserted-by":"crossref","first-page":"n1098","DOI":"10.1136\/bmj.n1098","volume":"373","author":"SE Daugherty","year":"2021","unstructured":"Daugherty, S. E. et al. Risk of clinical sequelae after the acute phase of SARS-CoV-2 infection: retrospective cohort study. BMJ 373, n1098 (2021).","journal-title":"BMJ"},{"key":"662_CR107","doi-asserted-by":"publisher","DOI":"10.1016\/s1473-3099(21)00460-6","author":"M Antonelli","year":"2021","unstructured":"Antonelli, M. et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. Lancet Infect. Dis. https:\/\/doi.org\/10.1016\/s1473-3099(21)00460-6 (2021).","journal-title":"Lancet Infect. Dis."},{"key":"662_CR108","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1001\/jama.2021.2091","volume":"325","author":"LR Feldstein","year":"2021","unstructured":"Feldstein, L. R. et al. Characteristics and outcomes of US children and adolescents with multisystem inflammatory syndrome in children (MIS-C) compared with severe acute COVID-19. JAMA 325, 1074\u20131087 (2021).","journal-title":"JAMA"},{"key":"662_CR109","unstructured":"Ministry of Health. Israel Ministry of Health COVID-19 Dashboard https:\/\/datadashboard.health.gov.il\/COVID-19\/general (2021)."},{"key":"662_CR110","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.16420","volume":"4","author":"AB Payne","year":"2021","unstructured":"Payne, A. B. et al. Incidence of multisystem inflammatory syndrome in children among US persons infected with SARS-CoV-2. JAMA Netw. Open 4, e2116420 (2021).","journal-title":"JAMA Netw. Open"},{"key":"662_CR111","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1056\/NEJMoa2109682","volume":"385","author":"MP O\u2019Brien","year":"2021","unstructured":"O\u2019Brien, M. P. et al. Subcutaneous REGEN-COV antibody combination to prevent Covid-19. N. Engl. J. Med. 385, 1184\u20131195 (2021).","journal-title":"N. Engl. J. Med."},{"key":"662_CR112","doi-asserted-by":"publisher","DOI":"10.1101\/2021.05.19.21257469","author":"DM Weinreich","year":"2021","unstructured":"Weinreich, D. M. et al. REGEN-COV antibody cocktail clinical outcomes study in Covid-19 outpatients. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2021.05.19.21257469 (2021).","journal-title":"medRxiv"},{"key":"662_CR113","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S1473-3099(20)30911-7","volume":"21","author":"B Young","year":"2021","unstructured":"Young, B., Tan, T. T. & Leo, Y. S. The place for remdesivir in COVID-19 treatment. Lancet Infect. Dis. 21, 20\u201321 (2021).","journal-title":"Lancet Infect. Dis."},{"key":"662_CR114","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1093\/cid\/ciab070","volume":"73","author":"PD Bieniasz","year":"2021","unstructured":"Bieniasz, P. D. The case against delaying severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccine boosting doses. Clin. Infect. Dis. 73, 1321\u20131323 (2021).","journal-title":"Clin. Infect. Dis."},{"key":"662_CR115","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/s41577-021-00544-9","volume":"21","author":"S Cobey","year":"2021","unstructured":"Cobey, S., Larremore, D. B., Grad, Y. H. & Lipsitch, M. Concerns about SARS-CoV-2 evolution should not hold back efforts to expand vaccination. Nat. Rev. Immunol. 21, 330\u2013335 (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"662_CR116","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006194","volume":"13","author":"K Debbink","year":"2017","unstructured":"Debbink, K. et al. Vaccination has minimal impact on the intrahost diversity of H3N2 influenza viruses. PLoS Pathog. 13, e1006194 (2017).","journal-title":"PLoS Pathog."},{"key":"662_CR117","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1126\/science.abh2644","volume":"372","author":"NR Faria","year":"2021","unstructured":"Faria, N. R. et al. Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil. Science 372, 815\u2013821 (2021).","journal-title":"Science"},{"key":"662_CR118","doi-asserted-by":"publisher","DOI":"10.1101\/2021.09.28.21264260","author":"RJ Harris","year":"2021","unstructured":"Harris, R. J. et al. Impact of vaccination on household transmission of SARS-COV-2 in England. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2021.09.28.21264260 (2021).","journal-title":"medRxiv"},{"key":"662_CR119","doi-asserted-by":"publisher","DOI":"10.1101\/2021.05.27.21257896","author":"J Salo","year":"2021","unstructured":"Salo, J. et al. The indirect effect of mRNA-based Covid-19 vaccination on unvaccinated household members. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2021.05.27.21257896 (2021).","journal-title":"medRxiv"},{"key":"662_CR120","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1038\/s41591-021-01407-5","volume":"27","author":"O Milman","year":"2021","unstructured":"Milman, O. et al. Community-level evidence for SARS-CoV-2 vaccine protection of unvaccinated individuals. Nat. Med. 27, 1367\u20131369 (2021).","journal-title":"Nat. Med."},{"key":"662_CR121","doi-asserted-by":"publisher","DOI":"10.1016\/s2666-5247(21)00219-6","author":"JP Townsend","year":"2021","unstructured":"Townsend, J. P. et al. The durability of immunity against reinfection by SARS-CoV-2: a comparative evolutionary study. Lancet Microbe https:\/\/doi.org\/10.1016\/s2666-5247(21)00219-6 (2021).","journal-title":"Lancet Microbe"},{"key":"662_CR122","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1086\/515616","volume":"178","author":"L Simonsen","year":"1998","unstructured":"Simonsen, L. et al. Pandemic versus epidemic influenza mortality: a pattern of changing age distribution. J. Infect. Dis. 178, 53\u201360 (1998).","journal-title":"J. Infect. Dis."},{"key":"662_CR123","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1126\/science.abe6522","volume":"371","author":"JS Lavine","year":"2021","unstructured":"Lavine, J. S., Bjornstad, O. N. & Antia, R. Immunological characteristics govern the transition of COVID-19 to endemicity. Science 371, 741\u2013745 (2021).","journal-title":"Science"},{"key":"662_CR124","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/S0140-6736(21)02046-8","volume":"398","author":"PR Krause","year":"2021","unstructured":"Krause, P. R. et al. Considerations in boosting COVID-19 vaccine immune responses. Lancet 398, 1377\u20131380 (2021).","journal-title":"Lancet"},{"key":"662_CR125","doi-asserted-by":"publisher","DOI":"10.1093\/biostatistics\/kxaa037","author":"DA Follmann","year":"2020","unstructured":"Follmann, D. A. & Dodd, L. Immune correlates analysis using vaccinees from test negative designs. Biostatistics https:\/\/doi.org\/10.1093\/biostatistics\/kxaa037 (2020).","journal-title":"Biostatistics"},{"key":"662_CR126","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41551-020-00672-y","volume":"5","author":"Z Wang","year":"2021","unstructured":"Wang, Z. et al. Microneedle patch for the ultrasensitive quantification of protein biomarkers in interstitial fluid. Nat. Biomed. Eng. 5, 64\u201376 (2021).","journal-title":"Nat. Biomed. Eng."}],"container-title":["Nature Reviews Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41577-021-00662-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41577-021-00662-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41577-021-00662-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T08:16:29Z","timestamp":1641284189000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41577-021-00662-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,7]]},"references-count":126,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["662"],"URL":"https:\/\/doi.org\/10.1038\/s41577-021-00662-4","relation":{},"ISSN":["1474-1733","1474-1741"],"issn-type":[{"value":"1474-1733","type":"print"},{"value":"1474-1741","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,7]]},"assertion":[{"value":"16 November 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.L. reports institutional grant funding from Pfizer, consulting\/honoraria from Bristol Myers Squibb, Janssen, Merck, Sanofi Pasteur, Peter Diamandis\/Abundance Platinum, and unpaid advice to One Day Sooner, Pfizer, Janssen, AstraZeneca, Covaxx (United Biomedical), and the Coalition for Epidemic Preparedness Innovations (CEPI). The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines, which list F.K. as co-inventor. Mount Sinai has spun out a company, Kantaro, to market serological tests for SARS-CoV-2. F.K. has consulted for Merck and Pfizer (before 2020) and is currently consulting for Pfizer, Seqirus and Avimex. The Krammer laboratory is also collaborating with Pfizer on animal models of SARS-CoV-2. R.D.B. reports past institutional grants to Clalit Research Institute from Pfizer, outside the submitted work and unrelated to COVID-19, with no direct or indirect personal benefits. G.R.-Y. has received a research grant from Pfizer on an unrelated topic (pneumococcal infections) and has received honoraria from Teva and MSD for presentations given (on fluid contamination and vaccine rollout). Y.L. has received a research grant from Pfizer on an unrelated topic (tick-borne encephalitis).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}